Medicare Increases Payment Rates for Most Physicians

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 10 No 1
Volume 10
Issue 1

WASHINGTON-Physicians will receive an average 4.5% increase in Medicare payment rates in 2001, the Health Care Financing Administration (HCFA) announced. Increases will range from nothing to 12%, depending on specialty.

WASHINGTON—Physicians will receive an average 4.5% increase in Medicare payment rates in 2001, the Health Care Financing Administration (HCFA) announced. Increases will range from nothing to 12%, depending on specialty.

Those paid under the classification hematology/oncology will receive a 6% payment increase; radiation oncologists will get 3%; and internal medicine physicians, 5%. Neurosurgeons received 1%, general surgeons, 2%; and obstetricians/gynecologists and urologists each received 6%.

Medicare payments will vary for specific services because the agency is in the midst of implementing a new payment system for physician practice expenses based on the resources involved in treating patients rather than on physician’s historical charges.

Recent Videos
The mechanism of CTO1681 may allow it to reduce the production of a broad range of proinflammatory cytokines in DLBCL.
Younger and fitter patients with relapsed/refractory multiple myeloma were more likely to receive bispecific antibodies in community oncology settings.
Mechanistic treatment benefits were observed in the phase 2 STEM trial for patients with multiple myeloma.
Data from a retrospective cohort study showed that one-fifth of patients with multiple myeloma received bispecific antibodies in rural community settings.
Being able to treat patients with cevostamab who have multiple myeloma after 1 to 3 prior lines of therapy vs 4 lines may allow for better outcomes.
Using the monitoring of symptoms and quality of life platform may provide a quick and efficient system for patients to submit outcome data.
2 experts are featured in this series.
With many treatments emerging in the EGFR-mutated lung cancer landscape, sequencing therapy has emerged as a key consideration for these patients.